Follow us for updates
© 2021
Read the Story →

Pfizer Claims Its Anti-COVID Pill is 89% Effective vs Severe Disease

After vaccines, come the treatments.
by Agence France Presse
Just now
Photo/s: Jerome Ascaño

WASHINGTON -- Pfizer said Friday that a clinical trial of its pill to treat COVID-19 had shown it is highly effective, hailing it is as a big step toward ending the pandemic. 

A simple pill to treat the coronavirus at home has been sought since the start of the global health crisis. So far all treatments have been either intravenous or vaccine shots.

Pfizer's is the second anti-COVID pill after that of Merck, which is actually an influenza medicine rebranded to fight the coronavirus. Pfizer's has been created specifically to fight COVID.

The Pfizer drug called Paxlovid achieved an 89% reduction in risk of hospitalization or death among adult patients with COVID who are at high risk of progressing to severe illness, the U.S. company said.

The results from the middle-to-late stage clinical trial were so strong that Pfizer will stop recruiting new people for the trial, it said.

Pfizer will submit the data to the Food and Drug Administration as soon as possible as part of its "rolling submission" for Emergency Use Authorization.

Continue reading below ↓

"Today's news is a real game-changer in the global efforts to halt the devastation of this pandemic," said Pfizer CEO Albert Bourla.

"These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients' lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of 10 hospitalizations," he added.

Bourla told CNN he hopes the company can submit its authorization request before the Thanksgiving holiday, which this year falls on Nov. 25.

President Joe Biden said in remarks at the White House that the government has already secured millions of doses of the new medication.

Continue reading below ↓
Recommended Videos

He said the pill "would be another tool in our toolbox to protect people from the worst outcomes of COVID."

The main analysis of the Pfizer pill data looked at numbers from 1,219 adults in North and South America, Europe, Africa and Asia.

Continue reading below ↓

In the days immediately after symptoms appeared, some of them were given the experimental drug and others got a placebo -- for five days, every 12 hours.

Ten people who took the placebo died, while among those who got the Pfizer medication, none did.


Ayala Health to Sell Merck Anti-COVID Pill in Philippines

Merck's COVID Pill Hailed After Cutting Hospitalizations by Half

Drugmakers Eye Oral Antivirals to Cure COVID-19

The search for a pill

Several companies are working on so-called oral antivirals, which would mimic what the drug Tamiflu does for influenza and prevent the disease from progressing to severe.

Britain on Thursday became the first country to approve an anti-COVID pill, as it greenlit the use of Merck's antiviral drug called molnupiravir to treat patients suffering from mild to moderate coronavirus. 

Pfizer's product is known as a "protease inhibitor" and has been shown in lab testing to jam up the virus' replication machinery.

Continue reading below ↓

If it works in real life, it will likely only be effective at the early stages of infection. 

By the time COVID progresses to severe disease, the virus has largely stopped replicating and patients suffer from an overactive immune response.

Until now, COVID therapeutics such as monoclonal antibodies and Gilead's remdesivir -- authorized for use in the EU under the name Veklury -- have been administered intravenously.

Merck's molnupiravir was initially developed as an inhibitor of influenza and respiratory syncytial virus -- two other important acute respiratory infections -- by a team at Emory University in Atlanta, Georgia.

Britain, which has been one of the countries hardest hit by the pandemic, announced on October 20 that it had ordered 480,000 doses of molnupiravir.

Pfizer is carrying out two other clinical trials with its pill: among people who are not at risk of progressing to severe Covid, and among people close to someone with COVID to see if it protects them against the illness.

Continue reading below ↓

Besides Pfizer and Merck, the Swiss pharma giant Roche is also working on a COVID pill.

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.